After a rough go with the FDA sent its shares spiraling downward, Amarin ($AMRN) has at last found a partner to help commercialize its fish-oil-derived pill for high triglycerides. The biotech has teamed up with Japanese statin specialist Kowa Pharmaceuticals to nearly triple its U.S. sales force and try to move the needle on Vascepa, which has been a commercial disappointment since winning FDA approval in 2012. Article